@article{JGO6751,
author = {Smit Singla and Charles M. LeVea and Venkata K. Pokuri and Kristopher M. Attwood and Michael M. Wach and Garin M. Tomaszewski and Boris Kuvshinoff and Renuka Iyer},
title = {Ki67 score as a potential predictor in the selection of liver-directed therapies for metastatic neuroendocrine tumors: a single institutional experience},
journal = {Journal of Gastrointestinal Oncology},
volume = {7},
number = {3},
year = {2016},
keywords = {},
abstract = {Background: Neuroendocrine tumors (NETs) metastatic to the liver are treated with transarterial radioembolization (TARE) using yttrium-90 (Y-90) microspheres or transarterial chemoembolization (TACE). However the criteria for patient selection are not well defined. We sought to determine if Ki67 score could help select patients for one therapy over the other in the management of hepatic neuroendocrine metastases.
Methods: Single institution analysis of patients treated with Y-90 or TACE between 2001 and 2014. Pathologists blinded to clinical information performed Ki67 staining. Data were analyzed using multivariate association for survival outcomes.
Results: Amongst 72 patients (male: 39, female: 33, median age: 57 years) with metastatic NET, the most common site of origin was small bowel (n=35, 49%), while pancreas constituted 32% (n=23). Forty-four patients were treated with Y-90 (61%) and 28 patients received TACE (39%). Ki67 score was available in 28 patients (64%) treated with Y-90 and 16 patients (57%) with TACE. Within Y-90 group, there was greater use of Sandostatin (95% vs. 75%, P=0.02) and less number of total treatments completed (89% vs. 46%, P},
issn = {2219-679X}, url = {https://jgo.amegroups.org/article/view/6751}
}